Lv3
290 积分 2025-10-04 加入
From bench to bedside: current development and emerging trend of KRAS-targeted therapy
2个月前
已完结
Combined inhibition of hexokinase 2 and pyruvate dehydrogenase surmounts SHP2 inhibitor resistance in non-small cell lung cancer with hybrid metabolic state harboring KRAS Q61H mutation
2个月前
已完结
Dealing with KRAS G12C inhibition in non-small cell lung cancer (NSCLC) – biology, clinical results and future directions
2个月前
已完结
RIT1M90I is a driver of lung adenocarcinoma tumorigenesis and resistance to targeted therapy
2个月前
已完结
JAB-3312, a Potent Allosteric SHP2 Inhibitor That Enhances the Efficacy of RTK/RAS/MAPK and PD-1 Blockade Therapies
3个月前
已完结
Proteomic analyses identify targets, pathways, and cellular consequences of oncogenic KRAS signaling
3个月前
已完结
Unveiling the role of KRAS in tumor immune microenvironment
3个月前
已完结
Advances in the Basic Sciences in Thoracic Oncology in the Last 20 Years and Their Translational Impact
3个月前
已完结
Challenges of small cell lung cancer heterogeneity and phenotypic plasticity
4个月前
已完结
Navigating the landscape of EGFR TKI resistance in EGFR-mutant NSCLC — mechanisms and evolving treatment approaches
4个月前
已完结
皖公网安备34019202002308
